Roche Signs Up to $2 Billion Deal With Atavistik for Allosteric Cardiometabolic Drugs

What happened

Earlier this week, Roche agreed to a drug discovery partnership with Atavistik Bio that could be worth up to $2 billion. The deal was announced on Thursday, Sept. 24, and BioSpace reported that Roche will pay $70 million upfront, with up to $1.9 billion in milestone payments and tiered royalties.

The partnership will focus on cardiovascular, renal and metabolic (CVRM) targets using Atavistik’s allosteric drug discovery platform.

Deal details

• Upfront: $70 million.
• Milestones: Up to $1.9 billion.
• Total potential value: Up to $2 billion.
• Royalties: Tiered royalties.
• Roles: Atavistik leads discovery and research for several CVRM targets; Roche handles preclinical, clinical and commercial work.

Atavistik’s platform, called AMPS, finds novel functional binding pockets on proteins that have historically been hard to modulate with small molecules. Allosteric drugs bind to a site other than a protein’s main active site, changing its shape or activity, which can allow more selective effects.

The company’s own pipeline focuses on rare hematology. Its lead asset, ATV-1601, an oral allosteric inhibitor selective for AKT1, received FDA fast track designation in June 2026 for hereditary hemorrhagic telangiectasia and is in a Phase 1/2 trial.

“Treating CVRM diseases remains a core strategic priority for Roche,” said Boris Zaïtra, Roche’s head of corporate business development.

Roche’s cardiometabolic push

BioSpace placed the deal within a broader Roche buildup in the area:

• Roche opened a new Boston research and development center through Genentech the week before the deal, focused exclusively on CVRM diseases.
• In 2023, it acquired obesity biotech Carmot Therapeutics for $2.7 billion upfront.
• In 2025, it bought MASH-focused 89bio in a deal worth up to $3.5 billion.

Why it matters for the sector

Cardiometabolic disease, including obesity, diabetes, heart failure and kidney disease, has become a central area of investment for large drugmakers following the commercial success of GLP-1 medicines. Companies that were not early leaders in obesity have been building positions through acquisitions and partnerships, and Roche has been among the most active.

The Atavistik agreement takes a different route from Roche’s earlier buys. Rather than acquiring late-stage obesity assets, it focuses on discovering new small molecules for difficult targets, a longer-term bet that could produce oral drugs for conditions that currently require injections or lack effective therapies.

Allosteric drug discovery has attracted interest because it can open up targets that were considered undruggable with traditional approaches. Platforms that systematically map such binding sites are valuable to partners that want to pursue multiple targets at once.

The deal was one of several large pharma-biotech partnerships announced on Sept. 24, a day that also included Lilly’s collaboration with InnoCare and Genentech’s agreement with Earendil, underscoring the pace of licensing activity in the second half of September.

For Atavistik, the upfront payment helps fund both the partnered work and its own rare hematology programs.

The upfront-to-total ratio in the Atavistik agreement, $70 million against a potential $2 billion, is typical of early discovery collaborations. Most of the value depends on candidates entering the clinic and reaching approval, which can take a decade or longer for new small molecules.

For Roche, the deal adds a discovery engine to complement its later-stage cardiometabolic acquisitions, giving it programs at different points in the development cycle.

What to watch

• Which CVRM targets Roche and Atavistik pursue first.
• Progress of ATV-1601 in hereditary hemorrhagic telangiectasia.
• Additional Roche deals in obesity and cardiometabolic disease.
• Output from Genentech’s new Boston CVRM research center.

Sources: BioSpace

Allosteric Drugs, Explained

Most traditional small-molecule drugs work by fitting into a protein’s active site, the pocket where it does its main job, much as a key fits a lock. This is called orthosteric binding. Allosteric drugs instead bind somewhere else on the protein, and that binding changes the protein’s shape or behavior.

Why that can matter

• Selectivity. Related proteins often share nearly identical active sites, making it hard to block one without affecting others. Allosteric sites tend to vary more, so a drug can be designed to act on one family member while sparing its relatives.
• New targets. Some proteins lack a usable active site for drugs, or their active site is shaped in ways that defeat drug design. An allosteric pocket can offer another way in.
• Fine-tuning. Allosteric drugs can dial activity up or down rather than shutting it off completely, which may be useful in diseases where a protein’s normal function is still needed.

The difficulty is finding these pockets. Many are hidden or appear only when a protein moves, which is why platforms that map them systematically attract partners.

The AKT1 Example

Atavistik’s lead program illustrates the selectivity point. AKT is a family of three closely related enzymes, AKT1, AKT2 and AKT3, involved in cell growth and metabolism. Blocking all three can affect blood sugar control and other functions. A drug selective for AKT1 aims to act on the version relevant to the disease while limiting effects on the others.

Hereditary hemorrhagic telangiectasia, the condition named in the fast track designation, is an inherited disorder in which some blood vessels form abnormally, creating fragile connections between arteries and veins. These can bleed easily, and frequent nosebleeds are a common symptom. Abnormal vessels can also occur in organs such as the lungs, liver and brain. Patients should discuss diagnosis and treatment with their own physicians.

Why Cardiovascular, Renal and Metabolic Diseases Are Grouped

The heart, kidneys and metabolism are closely linked. Obesity and type 2 diabetes raise the risk of heart disease and kidney disease; kidney disease in turn strains the heart; and heart failure can worsen kidney function. Because these conditions so often occur together, drugmakers increasingly organize research around the combined area, and some medicines originally developed for one condition have shown benefits across others.

Questions Readers Ask

What does Roche take on after discovery?

Under the described roles, preclinical, clinical and commercial work, which together account for most of the cost and time of bringing a drug to market.

Why invest in early discovery after buying later-stage assets?

Combining late-stage acquisitions with early discovery gives a company programs maturing at different times, helping sustain a pipeline over many years.

This article is for general information only and is not investment or medical advice.